2024 | Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study | THYROID |
2023 | Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy
| ACTA ONCOLOGICA |
2023 | Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis
| JOURNAL OF THORACIC ONCOLOGY |
2023 | Management of HER2 alterations in non-small cell lung cancer - The past, present, and future | LUNG CANCER |
2023 | Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
| LUNG CANCER |
2023 | Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
| JOURNAL OF THORACIC ONCOLOGY |
2023 | Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial
| JAMA ONCOLOGY |
2023 | Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions | NEW ENGLAND JOURNAL OF MEDICINE |
2023 | Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
2023 | Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study
| JOURNAL OF THORACIC ONCOLOGY |
2023 | A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)
| CANCERS |
2023 | Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
| JOURNAL OF THORACIC ONCOLOGY |
2023 | Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
| NATURE MEDICINE |
2023 | A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab
| FUTURE ONCOLOGY |
2023 | Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies
| CANCERS |
2023 | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 | JOURNAL OF CLINICAL ONCOLOGY |
2023 | Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA | CLINICAL CANCER RESEARCH |
2023 | A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
| ESMO OPEN |
2023 | Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
| TRANSLATIONAL LUNG CANCER RESEARCH |
2023 | Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea
| Cancer Treatment and Research Communications |
2023 | A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
| ESMO OPEN |
2023 | Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study | LUNG CANCER |
2023 | Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
| JOURNAL OF THORACIC ONCOLOGY |
2023 | Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
| ANNALS OF ONCOLOGY |
2023 | Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia | JOURNAL OF THORACIC ONCOLOGY |
2023 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
| JOURNAL OF CLINICAL ONCOLOGY |
2023 | Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
| LUNG CANCER |
2023 | Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
| CANCER RESEARCH AND TREATMENT |
2023 | Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset
| FRONTIERS IN ONCOLOGY |
2023 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
| ONCOLOGIST |
2023 | Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications
| CLINICAL LUNG CANCER |
2023 | The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer
| KOREAN JOURNAL OF INTERNAL MEDICINE |
2023 | Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
| NATURE COMMUNICATIONS |
2023 | A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation
| CANCER |
2023 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
| JOURNAL OF CLINICAL ONCOLOGY |
2023 | Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide
| FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY |
2023 | Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON
| CANCER DISCOVERY |
2023 | Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC | CLINICAL CANCER RESEARCH |
2023 | A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data | FUTURE ONCOLOGY |
2023 | Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2023 | Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors | TARGETED ONCOLOGY |
2023 | Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
| CANCER RESEARCH AND TREATMENT |
2022 | Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2022 | Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
2022 | A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11) | CLINICAL LUNG CANCER |
2022 | YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment
| FRONTIERS IN CHEMISTRY |
2022 | Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis
| BIOORGANIC & MEDICINAL CHEMISTRY LETTERS |
2022 | Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1) | EUROPEAN JOURNAL OF CANCER |
2022 | Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial | EUROPEAN JOURNAL OF CANCER |
2022 | Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation | EUROPEAN JOURNAL OF CANCER |